{ "entity_id": "B-003290", "folder": "Haemovigilance-Advisory-Committee", "name": "Haemovigilance Advisory Committee", "type": "Statutory Body", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.blood.gov.au/haemovigilance-reporting", "data_status": "rich", "completeness": { "has_strategy_brief": true, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": false, "has_kpi_results": false, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_ideas": true, "has_artifacts": true, "n_ideas": 12, "n_legislation": 0, "n_artifacts": 8, "n_kpi_targets": 0, "n_kpi_results": 0, "n_outcomes": 1, "verified_own_data": true }, "strategy_profile": { "status": "published", "confidence": "high", "summary": "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS).", "official_site_url": "https://www.blood.gov.au/haemovigilance-reporting", "source_documents": [ { "type": "strategie", "title": "Australian Haemovigilance Minimum Data Set", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf", "period": "2025", "confidence": "medium" }, { "type": "annual_report", "title": "Annual Report", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "period": "2025", "confidence": "high" }, { "type": "corporate_plan", "title": "Corporate Plan", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "period": "2025", "confidence": "high" } ], "purpose": { "text": "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS).", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 4, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=4" }, "vision": null, "strategic_priorities": [], "values": [], "outcomes": [ { "name": "Outcome: Quality and Safety of Blood Transfusions", "description": "The AHMDS enables consistent data collection and analysis of transfusion related adverse events occurring in Australian health service organisations to improve the quality of national haemovigilance reporting.", "activities": [ "Data collection and analysis", "Reporting and monitoring" ], "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 4, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=4" } ], "performance_measures": [], "document_alignment_terms": { "must_support": [ "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS)." ], "watch_terms": [], "avoid_claiming_without_evidence": [] }, "review_note": "" }, "strategy_brief_md": "# Haemovigilance Advisory Committee — Strategy Brief\n\n**Reporting period**: 2024-25\n**Corporate plan in force**: 2025-26\n**Corporate Plan**: [2025-26](https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)\n\n## Our purpose / purposes\n\n> The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS). [[CP p.4](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=4)(https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf#page=4)]\n\n## Outcomes\n\n### Outcome: Quality and Safety of Blood Transfusions\nThe AHMDS enables consistent data collection and analysis of transfusion related adverse events occurring in Australian health service organisations to improve the quality of national haemovigilance reporting. [[CP p.4](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=4)(https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf#page=4)]\n\n**Key activities:**\n- Data collection and analysis\n- Reporting and monitoring", "strategy_overview_evidence_md": null, "internal_strategy_evidence_md": "# Haemovigilance Advisory Committee - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:22:12.689058+00:00\n**Entity ID**: B-003290\n**Entity type**: Statutory Body\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: https://www.blood.gov.au/haemovigilance-reporting\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| other-pdfs | 5 |\n| pages | 3 |\n| strategies | 1 |\n\n## Executive Readout\n\n### Purpose\n\n- [Page 12]\nHealth industry relevant organisation—main\nactivity type\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Health industry relevant organisation type\nMETEOR identifier: 372264\nDefinition: Describes a health industry relevant organisation based on\nits main activity, as represented by a code.*\nData Element Concept: Health industry relevant organisation—main activity type\nRepresentational attributes\nRepresentation class: Code\nData type: Number\nFormat: NNN\nMaximum character length: 3\nPermissible values: Value Meaning\nMain health care services organisation\n101 Hospital – public\n102 Hospital – private (excluding private free-\nstanding day hospital facility)\n103 Hospital – private free-standing day hospital\nfacility (excluding private non free-standing\nday hospital facility)\n104 Residential facility – mental health care\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- CODE 9 Not stated/inadequately described\nComments: Mapping of the remoteness codes between the current\nAHMDS and the superseded 2010 NHDD, 2015 AHMDS:\nCurrent 2015 2010\n1 1 RA 1\n2 2 RA 2\n3 3 RA 3\n4 4 RA 4\n5 5 RA 5\n6 6 Not Included\n9 Not included Not included\nRationale for inclusion:\nThis data element will be used to analyse the difference in the occurrence and outcome of adverse\nevents in different geographic areas.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Table 12: Contributory factors for all adverse events, 2015-16 to 2019-20\n% Change from\nSummary Data 2015-16 2016-17 2017-18 2018-19 2019-20\n2018-19\nNone identified 286 256 171 245 330 34.7%\nProduct characteristic 360 319 193 182 174 -4.4%\nTransfusion in emergency setting 17 11 13 19 24 26.3%\nDeliberate clinical decision 36 33 29 40 46 15.0%\nPrescribing/ordering 15 18 12 5 5 0.0%\nSpecimen collection/labelling 0 0 1 3 2 -33.3%\nLaboratory (testing/dispensing) 23 11 13 9 16 77.8%\nTransport, storage, handling 1 1 1 1 1 0.0%\nAdministration of product 15 18 42 10 64 540.0%\nIndications do not meet guidelines 2 9 8 5 6 20.0%\nProcedure did not adhere to hospital\n15 18 19 9 7 -22.2%\ntransfusion guidelines\nOther 20 58 53 48 81 68.8%\nContributory factors for all adverse events for 2019-20\nTable 13 shows a breakdown of reported contributory factors by adverse event and outcome\nseverity for 2019-20.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [pages 12,13,14,15]\nratory (testing/dispensing) 23 11 13 9 16 77.8%\nTransport, storage, handling 1 1 1 1 1 0.0%\nAdministration of product 15 18 42 10 64 540.0%\nIndications do not meet guidelines 2 9 8 5 6 20.0%\nProcedure did not adhere to hospital\n15 18 19 9 7 -22.2%\ntransfusion guidelines\nOther 20 58 53 48 81 68.8%\nContributory factors for all adverse events for 2019-20\nTable 13 shows a breakdown of reported contributory factors by adverse event and outcome\nseverity for 2019-20.\n• ‘Administration of product’ was reported to be associated with FNHTRs and allergic reactions\n• ‘Transfusion in emergency setting’ was reported to be associated with IBCTs\n• ‘Laboratory (testing/dispensing) was also reported to be associated with IBCTs (12), with two\nlife-threatening cases in 2019-20.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n\n### Role and Functions\n\n- [Page 18]\nPatient—outcome severity\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Outcome severity\nMETEOR identifier: Not applicable\nDefinition: Hierarchical categories to define harm done to the patient\nas a result of an adverse event. ∧\nData Element Concept: Patient—outcome severity\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: [X(21)]\nMaximum character length: 21\nPermissible values:\nValue Meaning\nNo morbidity No ill effects, no clinical effects\nMinor The recipient may have required medical\nmorbidity intervention (such as symptomatic\ntreatment) but lack of such would not\nhave resulted in permanent damage or\nimpairment of a body function\nSevere The recipient required in-patient\nmorbidity hospitalisation or prolongation of\nhospitalisation directly attributable to the\nevent; and/or\n- the adverse event resulted in\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- [pages 29,30,31,32]\nMore than one type of product that may cause the adverse event\nCell salvage Autologous cell salvage\nPre-deposit Autologous pre-deposit\nOther products Directed donation complying with Guidelines\nGranulocytes\nCollection and usage attributes\nGuide for use: The administered labile blood product or fresh blood\ncomponent can be coded as one of the categories\npresented.\n∧∧\nModified from 2010 National Haemovigilance Data Dictionary definition\nNational Blood Authority pg.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- [Page 36]\nTransfusion-related acute lung injury In patients with no evidence of acute lung injury (ALI) prior\n(TRALI) to transfusion, TRALI is diagnosed if a new ALI is present (all\nfive criteria should be met) during or within 6 hours of\ncompletion of transfusion :\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e.\ncirculatory overload)\n• No temporal relationship to an alternative risk\nfactor for ALI, during or within 6 hours of\ncompletion of transfusion.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Table 2a: Total donor adverse event rates per 10,000 donations for FY 2016-17 to 2019-20\nTotal adverse event rate per 10,000 donations Comparison of FY 19-20 with 18-19\n(rate change from previous year) Relative Risk (95% Confidence Interval; p value)\nDonation Type 2016-17 2017-18 2018-19 2019-20 Number of donations for one additional event\nWhole Blood 310.57 299.05 297.09 321.76 1.08 (1.06-1.10; p<0.001)\n(-6.51) (-11.52) (-1.96) (+24.67) 406\nPlasmapheresis 188.89 261.60 324.13 455.08 1.40 (1.38-1.43; <0.001)\n(-10.20) (+72.71) (+62.53) (+130.95) 77\nPlateletpheresis 753.63 976.17 1,047.14 990.15 0.95 (0.90-0.99; p=0.03)\n(-49.02) (+222.54) (+70.97) (-56.99) -176\nTotal 268.17 295.12 325.50 404.30 1.24 (1.23-1.26; p<0.001)\n(-10.89) (+26.95) (+30.38) (+78.80) 127\n24\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Plateletpheresis\nIn general, the donor adverse rate for plateletpheresis has significantly decreased primarily as a result of the\ndecrease in the rate of citrate reactions by 19.64% from 522.20 to 419.62 per 10,000 donations (RR; 0.80;\n95% CI: 0.75-0.87; p<0.001), and to a lesser extent the smaller decrease in vasovagal reactions by 4.2% from\n133.55 to 128.00 per 10,000 donations (RR: 0.96; 95% CI: 0.83-1.11; p=0.56).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 28]\nOFFICIAL\nTable 3a: Vasovagal rates in new and returned female and male whole blood donors for FY 2019-2020\nFemales Males\nNew or Returned Donor Events Donations Rate per Events Donation Rate per\n(n) (n) 10,000 (n) (n) 10,000\nReturned 2019-20 5,438 277,567 195.92 2,103 297,549 70.68\nReturned 2018-19 5,454 279,278 195.29 2,123 306,001 69.38\nNew 2019-20 5,452 73,098 745.85 2,792 53,261 524.21\nNew 2018-19 4,817 68,486 703.36 2,431 50,221 484.06\nRelative Risk (95% CI); p value Relative Risk (95% CI); p value\nComparison groups\n[number of donations for an extra event] [number of donations for an extra event]\nNew vs returned in 2019-20 3.81 (3.67-3.95; p<0.001) [19] 7.42 (7.01-7.84; p<0.001) [22]\nNew 2019 vs 2018 1.06 (1.02-1.10; p=0.002) [236] 1.08 (1.03-1.14; p=0.003) [249]\nReturning 2019 vs 2018 1.00 (0.97-1.04; p=0.87) 1.01 (0.96-1.08; p=0.55)\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n\n### Strategic Priorities\n\n- The National Blood Research and Development Strategic Priorities 2022-27 highlights the need for\nresearch in haemovigilance and in particular “Priority 3: Reduce donor and patient adverse events”.\n Source: `other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)`\n- [Page 36]\nTransfusion-related acute lung injury In patients with no evidence of acute lung injury (ALI) prior\n(TRALI) to transfusion, TRALI is diagnosed if a new ALI is present (all\nfive criteria should be met) during or within 6 hours of\ncompletion of transfusion :\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e.\ncirculatory overload)\n• No temporal relationship to an alternative risk\nfactor for ALI, during or within 6 hours of\ncompletion of transfusion.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Table 2a: Total donor adverse event rates per 10,000 donations for FY 2016-17 to 2019-20\nTotal adverse event rate per 10,000 donations Comparison of FY 19-20 with 18-19\n(rate change from previous year) Relative Risk (95% Confidence Interval; p value)\nDonation Type 2016-17 2017-18 2018-19 2019-20 Number of donations for one additional event\nWhole Blood 310.57 299.05 297.09 321.76 1.08 (1.06-1.10; p<0.001)\n(-6.51) (-11.52) (-1.96) (+24.67) 406\nPlasmapheresis 188.89 261.60 324.13 455.08 1.40 (1.38-1.43; <0.001)\n(-10.20) (+72.71) (+62.53) (+130.95) 77\nPlateletpheresis 753.63 976.17 1,047.14 990.15 0.95 (0.90-0.99; p=0.03)\n(-49.02) (+222.54) (+70.97) (-56.99) -176\nTotal 268.17 295.12 325.50 404.30 1.24 (1.23-1.26; p<0.001)\n(-10.89) (+26.95) (+30.38) (+78.80) 127\n24\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Plateletpheresis\nIn general, the donor adverse rate for plateletpheresis has significantly decreased primarily as a result of the\ndecrease in the rate of citrate reactions by 19.64% from 522.20 to 419.62 per 10,000 donations (RR; 0.80;\n95% CI: 0.75-0.87; p<0.001), and to a lesser extent the smaller decrease in vasovagal reactions by 4.2% from\n133.55 to 128.00 per 10,000 donations (RR: 0.96; 95% CI: 0.83-1.11; p=0.56).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 28]\nOFFICIAL\nTable 3a: Vasovagal rates in new and returned female and male whole blood donors for FY 2019-2020\nFemales Males\nNew or Returned Donor Events Donations Rate per Events Donation Rate per\n(n) (n) 10,000 (n) (n) 10,000\nReturned 2019-20 5,438 277,567 195.92 2,103 297,549 70.68\nReturned 2018-19 5,454 279,278 195.29 2,123 306,001 69.38\nNew 2019-20 5,452 73,098 745.85 2,792 53,261 524.21\nNew 2018-19 4,817 68,486 703.36 2,431 50,221 484.06\nRelative Risk (95% CI); p value Relative Risk (95% CI); p value\nComparison groups\n[number of donations for an extra event] [number of donations for an extra event]\nNew vs returned in 2019-20 3.81 (3.67-3.95; p<0.001) [19] 7.42 (7.01-7.84; p<0.001) [22]\nNew 2019 vs 2018 1.06 (1.02-1.10; p=0.002) [236] 1.08 (1.03-1.14; p=0.003) [249]\nReturning 2019 vs 2018 1.00 (0.97-1.04; p=0.87) 1.01 (0.96-1.08; p=0.55)\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Whilst the lower rates observed in older donors are largely attributed to donation\nexperience, an analysis of new donors less than 30 years compared with those 30 or older, demonstrates\nthat the younger cohort continued to have a significantly higher rate of vasovagal for both whole blood (for\nfemales 1069.94 vs 526.24; for males 813.82 vs 365.25; p<0.001) and plasma (for females 897.65 vs 595.37;\nfor males 638.16 vs 360.64; p<0.001), suggesting age as an independent risk (Table 3c).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [pages 28,29,30]\nturned 2019-20 vs 2018-19 1.03 (0.98-1.08; p=0.21) 1.15 (1.07-1.24; p<0.001)\nNew 2019-20 vs 2018-19 0.87 (0.83-0.92; p<0.001) [96] 0.91 (0.85-0.98; p=0.01) [225]\nDonor age and gender\nThe risk of a vasovagal is higher in females than males across all age groups and reduces with age in both\ngroups (Figure 1).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 29]\nOFFICIAL\nFigure 1: Vasovagal rate per 10,000 donations (across all donation types) for males and females by age group for\n2019-20\nTable 3c: Vasovagal rates for new donors aged less than 30 and 30 years and over\nFemales Males\nVasovagal Donations Rate per 10,000 Vasovagal Donations Rate per 10,000\nevents (n) (n) donations events (n) (n) donations\nWhole blood <30 3,159 29,525 1069.94 1,536 18,874 813.82\nWhole blood ≥ 30 2,293 43,573 526.24 1,256 34,387 365.25\nPlasmapheresis <30 1,483 16,521 897.65 703 11,016 638.16\nPlasmapheresis ≥30 1,335 22,423 595.37 697 19,327 360.64\nComparison cohorts Relative Risk (95% CI); p value Relative Risk (95% CI); p value\n[number of donations for an extra event] [number of donations for an extra event]\nWhole blood <30 vs ≥30 2.03 (1.93-2.14; p<0.001) [19] 2.23 (2.07-2.40; p<0.001) [23]\nPlasma, <30 vs ≥30 1.51 (1.40-1.62; p<0.001) [33] 1.77 (1.60-1.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Table 4b: Rates of vasovagal events with loss of consciousness per 10,000 donations 2016-17 to 2019-20\nDonation FY 2016-17 FY 2017-18 FY 2018-19 FY 2019-20 Comparison\nCategory 19/20 with 18/19\nn Rate per n Rate per n Rate per n Rate per Relative Risk P value\n10,000 10,000 10,000 10,000 (95% CI)\nWhole Blood 1,633 22.91 1,384 19.76 1,224 17.39 1,340 19.10 1.10 (1.02-1.19) p=0.02\nPlasmapheresis 415 7.17 543 8.40 718 9.63 752 9.14 0.95 (0.86-1.05) p=0.32\nPlateletpheresis 13 4.02 19 6.84 19 6.52 20 7.27 1.11 (0.60-2.09) p=0.73\nTotal 2,061 15.56 1,946 14.15 1,961 13.26 2,112 13.61 1.03 (0.97-1.09) p=0.41\n30\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Transfusion-related acute lung In patients with no evidence of acute lung injury (ALI) prior to\ninjury (TRALI) transfusion, TRALI is diagnosed if a new ALI is present (all five\ncriteria should be met) during or within 6 hours of completion of\ntransfusion:\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e. circulatory\noverload)\n• No temporal relationship to an alternative risk factor for\nALI, during or within 6 hours of completion of transfusion.\n Source: `other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)`\n\n## KPIs, Targets, and Where They Are At\n\n- Plateletpheresis\nIn general, the donor adverse rate for plateletpheresis has significantly decreased primarily as a result of the\ndecrease in the rate of citrate reactions by 19.64% from 522.20 to 419.62 per 10,000 donations (RR; 0.80;\n95% CI: 0.75-0.87; p<0.001), and to a lesser extent the smaller decrease in vasovagal reactions by 4.2% from\n133.55 to 128.00 per 10,000 donations (RR: 0.96; 95% CI: 0.83-1.11; p=0.56).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [pages 39,40,41,42,43]\ntransfusion: A dose/rate inappropriate for the • Avoidable use of emergency Rh D negative blood where group-specific or crossmatched\npatient’s needs, excluding those cases which result in TACO.\nblood was readily available for the patient or the laboratory could have supplied a more\n(SHOT definition modified)\nsuitable component, including use of Rh D negative blood when time would allow a more\nappropriate group to be remotely allocated from a remote release refrigerator system.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Product defect A product defect is blood or a blood String 5 True or\ncomponent which does not meet the quality, False\nsafety and efficacy requirements set in the\nTherapeutic Goods Order No.1021 and 882\napproved under the Therapeutic Goods Act\n1989 or which contains (remaining)\ncontaminating agents despite screening,\ntesting and processing having been undertaken\nproperly (e.g. product discarded after positive\ninfection test result following a window\nperiod).\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- [pages 44,45,46]\nonsidered the result of the\nimplementation of a process for vein grading in July 2022 which identified when it was appropriate for\nmore experienced phlebotomist to undertake the venipuncture.\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- [Page 18]\nPatient—outcome severity\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Outcome severity\nMETEOR identifier: Not applicable\nDefinition: Hierarchical categories to define harm done to the patient\nas a result of an adverse event. ∧\nData Element Concept: Patient—outcome severity\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: [X(21)]\nMaximum character length: 21\nPermissible values:\nValue Meaning\nNo morbidity No ill effects, no clinical effects\nMinor The recipient may have required medical\nmorbidity intervention (such as symptomatic\ntreatment) but lack of such would not\nhave resulted in permanent damage or\nimpairment of a body function\nSevere The recipient required in-patient\nmorbidity hospitalisation or prolongation of\nhospitalisation directly attributable to the\nevent; and/or\n- the adverse event resulted in\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- [Page 36]\nTransfusion-related acute lung injury In patients with no evidence of acute lung injury (ALI) prior\n(TRALI) to transfusion, TRALI is diagnosed if a new ALI is present (all\nfive criteria should be met) during or within 6 hours of\ncompletion of transfusion :\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e.\ncirculatory overload)\n• No temporal relationship to an alternative risk\nfactor for ALI, during or within 6 hours of\ncompletion of transfusion.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Denominator cohort and rates\nThe denominator cohort used to calculate donor adverse event rates were those attendances that progressed\nto a donation attempt and have a needle inserted, regardless of whether the target collection volume was\nachieved.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Table 2a: Total donor adverse event rates per 10,000 donations for FY 2016-17 to 2019-20\nTotal adverse event rate per 10,000 donations Comparison of FY 19-20 with 18-19\n(rate change from previous year) Relative Risk (95% Confidence Interval; p value)\nDonation Type 2016-17 2017-18 2018-19 2019-20 Number of donations for one additional event\nWhole Blood 310.57 299.05 297.09 321.76 1.08 (1.06-1.10; p<0.001)\n(-6.51) (-11.52) (-1.96) (+24.67) 406\nPlasmapheresis 188.89 261.60 324.13 455.08 1.40 (1.38-1.43; <0.001)\n(-10.20) (+72.71) (+62.53) (+130.95) 77\nPlateletpheresis 753.63 976.17 1,047.14 990.15 0.95 (0.90-0.99; p=0.03)\n(-49.02) (+222.54) (+70.97) (-56.99) -176\nTotal 268.17 295.12 325.50 404.30 1.24 (1.23-1.26; p<0.001)\n(-10.89) (+26.95) (+30.38) (+78.80) 127\n24\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 28]\nOFFICIAL\nTable 3a: Vasovagal rates in new and returned female and male whole blood donors for FY 2019-2020\nFemales Males\nNew or Returned Donor Events Donations Rate per Events Donation Rate per\n(n) (n) 10,000 (n) (n) 10,000\nReturned 2019-20 5,438 277,567 195.92 2,103 297,549 70.68\nReturned 2018-19 5,454 279,278 195.29 2,123 306,001 69.38\nNew 2019-20 5,452 73,098 745.85 2,792 53,261 524.21\nNew 2018-19 4,817 68,486 703.36 2,431 50,221 484.06\nRelative Risk (95% CI); p value Relative Risk (95% CI); p value\nComparison groups\n[number of donations for an extra event] [number of donations for an extra event]\nNew vs returned in 2019-20 3.81 (3.67-3.95; p<0.001) [19] 7.42 (7.01-7.84; p<0.001) [22]\nNew 2019 vs 2018 1.06 (1.02-1.10; p=0.002) [236] 1.08 (1.03-1.14; p=0.003) [249]\nReturning 2019 vs 2018 1.00 (0.97-1.04; p=0.87) 1.01 (0.96-1.08; p=0.55)\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Whilst the lower rates observed in older donors are largely attributed to donation\nexperience, an analysis of new donors less than 30 years compared with those 30 or older, demonstrates\nthat the younger cohort continued to have a significantly higher rate of vasovagal for both whole blood (for\nfemales 1069.94 vs 526.24; for males 813.82 vs 365.25; p<0.001) and plasma (for females 897.65 vs 595.37;\nfor males 638.16 vs 360.64; p<0.001), suggesting age as an independent risk (Table 3c).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [pages 28,29,30]\nturned 2019-20 vs 2018-19 1.03 (0.98-1.08; p=0.21) 1.15 (1.07-1.24; p<0.001)\nNew 2019-20 vs 2018-19 0.87 (0.83-0.92; p<0.001) [96] 0.91 (0.85-0.98; p=0.01) [225]\nDonor age and gender\nThe risk of a vasovagal is higher in females than males across all age groups and reduces with age in both\ngroups (Figure 1).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 29]\nOFFICIAL\nFigure 1: Vasovagal rate per 10,000 donations (across all donation types) for males and females by age group for\n2019-20\nTable 3c: Vasovagal rates for new donors aged less than 30 and 30 years and over\nFemales Males\nVasovagal Donations Rate per 10,000 Vasovagal Donations Rate per 10,000\nevents (n) (n) donations events (n) (n) donations\nWhole blood <30 3,159 29,525 1069.94 1,536 18,874 813.82\nWhole blood ≥ 30 2,293 43,573 526.24 1,256 34,387 365.25\nPlasmapheresis <30 1,483 16,521 897.65 703 11,016 638.16\nPlasmapheresis ≥30 1,335 22,423 595.37 697 19,327 360.64\nComparison cohorts Relative Risk (95% CI); p value Relative Risk (95% CI); p value\n[number of donations for an extra event] [number of donations for an extra event]\nWhole blood <30 vs ≥30 2.03 (1.93-2.14; p<0.001) [19] 2.23 (2.07-2.40; p<0.001) [23]\nPlasma, <30 vs ≥30 1.51 (1.40-1.62; p<0.001) [33] 1.77 (1.60-1.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Table 4b: Rates of vasovagal events with loss of consciousness per 10,000 donations 2016-17 to 2019-20\nDonation FY 2016-17 FY 2017-18 FY 2018-19 FY 2019-20 Comparison\nCategory 19/20 with 18/19\nn Rate per n Rate per n Rate per n Rate per Relative Risk P value\n10,000 10,000 10,000 10,000 (95% CI)\nWhole Blood 1,633 22.91 1,384 19.76 1,224 17.39 1,340 19.10 1.10 (1.02-1.19) p=0.02\nPlasmapheresis 415 7.17 543 8.40 718 9.63 752 9.14 0.95 (0.86-1.05) p=0.32\nPlateletpheresis 13 4.02 19 6.84 19 6.52 20 7.27 1.11 (0.60-2.09) p=0.73\nTotal 2,061 15.56 1,946 14.15 1,961 13.26 2,112 13.61 1.03 (0.97-1.09) p=0.41\n30\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Transfusion-related acute lung In patients with no evidence of acute lung injury (ALI) prior to\ninjury (TRALI) transfusion, TRALI is diagnosed if a new ALI is present (all five\ncriteria should be met) during or within 6 hours of completion of\ntransfusion:\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e. circulatory\noverload)\n• No temporal relationship to an alternative risk factor for\nALI, during or within 6 hours of completion of transfusion.\n Source: `other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| 95% | Whole blood\nTotal DAE rates for whole blood increased significantly by 8.3% from 297.09 per 10,000 donations in 2018-\n19 to 321.76 per 10,000 donations in 2019-20 (RR4:1.08; 95%CI5: 1.06-1.10; p<0.001). | `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)` |\n| 95% | The increase is\nattributed primarily to the significant increases observed in rates for vasovagal reactions (210.59 to 225.03\nper 10,000 donations; RR: 1.07; 95%CI: 1.05-1.09; p<0.001) and haematoma (57.19 to 64.62 to per 10,000\ndonations; RR: 1.13; 95%CI: 1.08-1.18; p<0.001). | `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)` |\n| 95% | There has not been an increase\nin the rates for haematomas requiring external care in 2019-20 compared with 2018-19 (1.14 per 10,000\ndonations in 2018-19 vs 0.96 per 10,000 donations in 2019-20; RR 0.84; 95%CI: 0.61-1.16; p=0.29),\nsuggesting the increase in reporting relates to more minor events. | `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)` |\n| 95% | The transition to the new machine has been associated with a reduction in vasovagal reactions, from 123.42\nin 2018-19 to 117.40 per 10,000 donations (RR: 0.95; 95%CI: 0.92-0.98; p<0.001). | `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)` |\n| 95% | Donor adverse events requiring external referral\nThe overall rate of events requiring external care has significantly reduced from 8.14 per 10,000 in 2018-19\nFY to 6.97 per 10,000 in 2019-20 (RR: 0.86; 95%CI: 0.79-0.93; p<0.001) (Table 5). | `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)` |\n\n## Key Achievements\n\n- [Page 8]\nPerson—age range\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Age Range\nMETEOR identifier: 290540 (modified)\nDefinition: The age range that best accommodates a person’s\ncompleted age in years, at the time of transfusion, as\nrepresented by a code.**\nData Element Concept: Person—age range\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: XX\nMaximum character length: 2\nPermissible values:\nValue Meaning\n1\n0-28 days (neonate)\n2 29 days - <1 year (infant)\n3 1-4 years\n4 5-9 years\n5 10-14 years\n6 15-17 years\n7\n18-24 years\n8\n25-34 years\n9\n35-44 years\n10\n45-54 years\n11\n55-64 years\n12\n65-74 years\n13\n75-84 years\n14\n85 years and older\n99 Not stated\nCollection and usage attributes\nGuide for use: Age range should be derived from a question on date of\nbirth or age at last birthday.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- 9\nhtaeD\ngninetaerht-efiL ytidibrom\nereveS\nytidibrom\nroniM\nytidibrom\noN\nton\nemoctuO elbaliava\nlatoT\nFNHTR 1 1 12 167 32 9 222\nAllergic 0 9 5 186 40 1 241\nTACO 0 8 12 31 8 1 60\nIBCT 1 1 2 2 15 10 31\nAnaphylactic 1 11 5 2 5 0 24\nDHTR 0 0 1 12 4 1 18\nAHTR 0 3 1 18 2 0 24\nTTI 0 3 1 0 5 3 12\nTRALI 0 2 0 0 0 0 2\nDSTR 0 0 0 2 23 0 25\nHypotensive 0 0 0 1 1 1 3\nABO 0 0 0 1 0 0 1\nTAD 0 1 0 3 2 1 7\nOther 0 0 0 1 4 0 5\nTotal 3 39 39 426 141 27 675\nPercent 0.4% 5.8% 5.8% 63.1% 20.9% 4.0% 100%\nTable 7 highlights that 61.5% of adverse events were reported to be red cell transfusions, followed\nby platelets (24.7%) and fresh frozen plasma (10.2%).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Table 14: Adverse event groups based on imputability score and outcome severity\nOutcome severity Imputability score\nExcluded or Unlikely / Not Assessable Definite (certain) / Probable (likely) / Possible\nDeath\nLife-threatening Transfusion-related SAE\nSevere morbidity\nNon-transfusion related AE\nMinor morbidity\nNo morbidity\nTransfusion-related non-SAE\nOutcome not\navailable\nTable 15 shows reported adverse events reclassified as per the rules defined above and the\nhighlights are:\n• most reports (75.7% or 2,282) are transfusion-related non-SAEs\n• transfusion-related SAEs reported represented 10.8% (326)\n• 13.5% (407) of all reports are non-transfusion related AEs.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 15]\nTable 9 highlights that 68% of adverse events were reported to be related to red cell transfusions,\ncompared to red cells units issued being 62% of total fresh blood products issued in 2020-21,\nfollowed by platelets (14%) and fresh frozen plasma (8%).\n Source: `other-pdfs/Haemovigilance-20Report-202020-21.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf)`\n- [Page 15]\nTable 9 highlights that 71% of adverse events were reported to be related to red cell transfusions,\ncompared to red cells units issued being 62% of total fresh blood products issued in 2021-22,\nfollowed by platelets (13%) and fresh frozen plasma (8%).\n Source: `other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)`\n- [Page 22]\nTable 2: All adverse events by clinical outcome severity, 2022-23\nFigure 26 highlights that\n• 39.6% of RBC transfusion adverse events and 26.5% of platelet transfusion adverse events\nwere FNHTRs.\n• 48.7% of platelet-related adverse events and 82.1% of FFP-related adverse events were\nallergic reactions\n• 14.5% of RBC transfusion adverse events were TACO cases.\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- [Page 31]\nTable 15 highlights from 2018-19 to 2022-23 that:\n• 46.6% (1,010 of 2,166) of RBC transfusion adverse events and 20.1% (143 of 710) of platelet\ntransfusion adverse events were FNHTRs.\n• 56.8% (403 of 710) of platelet-related adverse events, 72.6% (162 of 223) of FFP-related\nadverse events, 64.3% (27 of 42) cryoprecipitate transfusion adverse events and 90% (9 of\n10) cryo-depleted plasma transfusion adverse events were allergic reactions\n• 13.8% (299 of 2,166) of RBC transfusion adverse events were TACOs\n• 13.5% (30 of 223) of FFP transfusion adverse events were anaphylactic reactions.\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- [Page 36]\nTransfusion-related acute lung injury In patients with no evidence of acute lung injury (ALI) prior\n(TRALI) to transfusion, TRALI is diagnosed if a new ALI is present (all\nfive criteria should be met) during or within 6 hours of\ncompletion of transfusion :\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e.\ncirculatory overload)\n• No temporal relationship to an alternative risk\nfactor for ALI, during or within 6 hours of\ncompletion of transfusion.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Table 2a: Total donor adverse event rates per 10,000 donations for FY 2016-17 to 2019-20\nTotal adverse event rate per 10,000 donations Comparison of FY 19-20 with 18-19\n(rate change from previous year) Relative Risk (95% Confidence Interval; p value)\nDonation Type 2016-17 2017-18 2018-19 2019-20 Number of donations for one additional event\nWhole Blood 310.57 299.05 297.09 321.76 1.08 (1.06-1.10; p<0.001)\n(-6.51) (-11.52) (-1.96) (+24.67) 406\nPlasmapheresis 188.89 261.60 324.13 455.08 1.40 (1.38-1.43; <0.001)\n(-10.20) (+72.71) (+62.53) (+130.95) 77\nPlateletpheresis 753.63 976.17 1,047.14 990.15 0.95 (0.90-0.99; p=0.03)\n(-49.02) (+222.54) (+70.97) (-56.99) -176\nTotal 268.17 295.12 325.50 404.30 1.24 (1.23-1.26; p<0.001)\n(-10.89) (+26.95) (+30.38) (+78.80) 127\n24\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Plateletpheresis\nIn general, the donor adverse rate for plateletpheresis has significantly decreased primarily as a result of the\ndecrease in the rate of citrate reactions by 19.64% from 522.20 to 419.62 per 10,000 donations (RR; 0.80;\n95% CI: 0.75-0.87; p<0.001), and to a lesser extent the smaller decrease in vasovagal reactions by 4.2% from\n133.55 to 128.00 per 10,000 donations (RR: 0.96; 95% CI: 0.83-1.11; p=0.56).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 28]\nOFFICIAL\nTable 3a: Vasovagal rates in new and returned female and male whole blood donors for FY 2019-2020\nFemales Males\nNew or Returned Donor Events Donations Rate per Events Donation Rate per\n(n) (n) 10,000 (n) (n) 10,000\nReturned 2019-20 5,438 277,567 195.92 2,103 297,549 70.68\nReturned 2018-19 5,454 279,278 195.29 2,123 306,001 69.38\nNew 2019-20 5,452 73,098 745.85 2,792 53,261 524.21\nNew 2018-19 4,817 68,486 703.36 2,431 50,221 484.06\nRelative Risk (95% CI); p value Relative Risk (95% CI); p value\nComparison groups\n[number of donations for an extra event] [number of donations for an extra event]\nNew vs returned in 2019-20 3.81 (3.67-3.95; p<0.001) [19] 7.42 (7.01-7.84; p<0.001) [22]\nNew 2019 vs 2018 1.06 (1.02-1.10; p=0.002) [236] 1.08 (1.03-1.14; p=0.003) [249]\nReturning 2019 vs 2018 1.00 (0.97-1.04; p=0.87) 1.01 (0.96-1.08; p=0.55)\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Whilst the lower rates observed in older donors are largely attributed to donation\nexperience, an analysis of new donors less than 30 years compared with those 30 or older, demonstrates\nthat the younger cohort continued to have a significantly higher rate of vasovagal for both whole blood (for\nfemales 1069.94 vs 526.24; for males 813.82 vs 365.25; p<0.001) and plasma (for females 897.65 vs 595.37;\nfor males 638.16 vs 360.64; p<0.001), suggesting age as an independent risk (Table 3c).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- [Page 36]\nTransfusion-related acute lung injury In patients with no evidence of acute lung injury (ALI) prior\n(TRALI) to transfusion, TRALI is diagnosed if a new ALI is present (all\nfive criteria should be met) during or within 6 hours of\ncompletion of transfusion :\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e.\ncirculatory overload)\n• No temporal relationship to an alternative risk\nfactor for ALI, during or within 6 hours of\ncompletion of transfusion.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Table 2a: Total donor adverse event rates per 10,000 donations for FY 2016-17 to 2019-20\nTotal adverse event rate per 10,000 donations Comparison of FY 19-20 with 18-19\n(rate change from previous year) Relative Risk (95% Confidence Interval; p value)\nDonation Type 2016-17 2017-18 2018-19 2019-20 Number of donations for one additional event\nWhole Blood 310.57 299.05 297.09 321.76 1.08 (1.06-1.10; p<0.001)\n(-6.51) (-11.52) (-1.96) (+24.67) 406\nPlasmapheresis 188.89 261.60 324.13 455.08 1.40 (1.38-1.43; <0.001)\n(-10.20) (+72.71) (+62.53) (+130.95) 77\nPlateletpheresis 753.63 976.17 1,047.14 990.15 0.95 (0.90-0.99; p=0.03)\n(-49.02) (+222.54) (+70.97) (-56.99) -176\nTotal 268.17 295.12 325.50 404.30 1.24 (1.23-1.26; p<0.001)\n(-10.89) (+26.95) (+30.38) (+78.80) 127\n24\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 28]\nOFFICIAL\nTable 3a: Vasovagal rates in new and returned female and male whole blood donors for FY 2019-2020\nFemales Males\nNew or Returned Donor Events Donations Rate per Events Donation Rate per\n(n) (n) 10,000 (n) (n) 10,000\nReturned 2019-20 5,438 277,567 195.92 2,103 297,549 70.68\nReturned 2018-19 5,454 279,278 195.29 2,123 306,001 69.38\nNew 2019-20 5,452 73,098 745.85 2,792 53,261 524.21\nNew 2018-19 4,817 68,486 703.36 2,431 50,221 484.06\nRelative Risk (95% CI); p value Relative Risk (95% CI); p value\nComparison groups\n[number of donations for an extra event] [number of donations for an extra event]\nNew vs returned in 2019-20 3.81 (3.67-3.95; p<0.001) [19] 7.42 (7.01-7.84; p<0.001) [22]\nNew 2019 vs 2018 1.06 (1.02-1.10; p=0.002) [236] 1.08 (1.03-1.14; p=0.003) [249]\nReturning 2019 vs 2018 1.00 (0.97-1.04; p=0.87) 1.01 (0.96-1.08; p=0.55)\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Whilst the lower rates observed in older donors are largely attributed to donation\nexperience, an analysis of new donors less than 30 years compared with those 30 or older, demonstrates\nthat the younger cohort continued to have a significantly higher rate of vasovagal for both whole blood (for\nfemales 1069.94 vs 526.24; for males 813.82 vs 365.25; p<0.001) and plasma (for females 897.65 vs 595.37;\nfor males 638.16 vs 360.64; p<0.001), suggesting age as an independent risk (Table 3c).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [pages 28,29,30]\nturned 2019-20 vs 2018-19 1.03 (0.98-1.08; p=0.21) 1.15 (1.07-1.24; p<0.001)\nNew 2019-20 vs 2018-19 0.87 (0.83-0.92; p<0.001) [96] 0.91 (0.85-0.98; p=0.01) [225]\nDonor age and gender\nThe risk of a vasovagal is higher in females than males across all age groups and reduces with age in both\ngroups (Figure 1).\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 29]\nOFFICIAL\nFigure 1: Vasovagal rate per 10,000 donations (across all donation types) for males and females by age group for\n2019-20\nTable 3c: Vasovagal rates for new donors aged less than 30 and 30 years and over\nFemales Males\nVasovagal Donations Rate per 10,000 Vasovagal Donations Rate per 10,000\nevents (n) (n) donations events (n) (n) donations\nWhole blood <30 3,159 29,525 1069.94 1,536 18,874 813.82\nWhole blood ≥ 30 2,293 43,573 526.24 1,256 34,387 365.25\nPlasmapheresis <30 1,483 16,521 897.65 703 11,016 638.16\nPlasmapheresis ≥30 1,335 22,423 595.37 697 19,327 360.64\nComparison cohorts Relative Risk (95% CI); p value Relative Risk (95% CI); p value\n[number of donations for an extra event] [number of donations for an extra event]\nWhole blood <30 vs ≥30 2.03 (1.93-2.14; p<0.001) [19] 2.23 (2.07-2.40; p<0.001) [23]\nPlasma, <30 vs ≥30 1.51 (1.40-1.62; p<0.001) [33] 1.77 (1.60-1.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Table 4b: Rates of vasovagal events with loss of consciousness per 10,000 donations 2016-17 to 2019-20\nDonation FY 2016-17 FY 2017-18 FY 2018-19 FY 2019-20 Comparison\nCategory 19/20 with 18/19\nn Rate per n Rate per n Rate per n Rate per Relative Risk P value\n10,000 10,000 10,000 10,000 (95% CI)\nWhole Blood 1,633 22.91 1,384 19.76 1,224 17.39 1,340 19.10 1.10 (1.02-1.19) p=0.02\nPlasmapheresis 415 7.17 543 8.40 718 9.63 752 9.14 0.95 (0.86-1.05) p=0.32\nPlateletpheresis 13 4.02 19 6.84 19 6.52 20 7.27 1.11 (0.60-2.09) p=0.73\nTotal 2,061 15.56 1,946 14.15 1,961 13.26 2,112 13.61 1.03 (0.97-1.09) p=0.41\n30\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Transfusion-related acute lung In patients with no evidence of acute lung injury (ALI) prior to\ninjury (TRALI) transfusion, TRALI is diagnosed if a new ALI is present (all five\ncriteria should be met) during or within 6 hours of completion of\ntransfusion:\n• Acute onset\n• Hypoxemia\nPa0 / Fi0 < 300 mm Hg or\no 2 2\nOxygen saturation is < 90% on room air or\no\nOther clinical evidence\no\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e. circulatory\noverload)\n• No temporal relationship to an alternative risk factor for\nALI, during or within 6 hours of completion of transfusion.\n Source: `other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)`\n- Transfusion-related acute In patients with no evidence of acute lung injury (ALI) prior to\nlung injury (TRALI) transfusion, TRALI is diagnosed if a new ALI is present (all five\ncriteria should be met) during or within 6 hours of completion of\ntransfusion:\n• Acute onset\n• Hypoxemia\no Pa0 / Fi0 < 300 mm Hg or\n2 2\no Oxygen saturation is < 90% on room air or\no Other clinical evidence\n• Bilateral infiltrates on frontal chest radiograph\n• No evidence of left atrial hypertension (i.e. circulatory\noverload)\n• No temporal relationship to an alternative risk factor for\nALI, during or within 6 hours of completion of transfusion.\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- Table 1: Unadjusted total adverse event rates per 10,000 donations\nRate per 10,000 donations Comparison 2022-23 to 2021-22\nDonation type 19-20 20-21 21-22 22-23 RR2 (95% CI3; p value) Number of donations for % Change\none additional event*\nWhole blood 322.74 297.56 315.31 286.83 0.91 (0.89-0.93; p<0.001) -351 -9.03%\nPlasmapheresis 455.88 525.55 493.82 475.36 0.96 (0.95-0.98; p<0.001) -542 -3.74%\nPlateletpheresis 990.15 870.66 704.12 760.61 1.08 (1.01-1.15; p=0.02) +177 +8.02%\nTotal 405.17 429.57 413.92 392.50 0.95 (0.94-0.96; p<0.001) -467 -5.31%\n*a negative number indicates that the number of donations is for one less event\n2 Relative risk\n3 Confidence interval\nTable 2: Standardised* total adverse event rates per 10,000 donations\nRate per 10,000 donations Comparison 2022-23 to 2021-22\nDonation type 21-22 22-23 RR (95% CI; p value) Number of donations for % Change\none additional event\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- [pages 40,41,42,43,44]\nindicates that the number of donations is for one less event\n2 Relative risk\n3 Confidence interval\nTable 2: Standardised* total adverse event rates per 10,000 donations\nRate per 10,000 donations Comparison 2022-23 to 2021-22\nDonation type 21-22 22-23 RR (95% CI; p value) Number of donations for % Change\none additional event\nWhole blood 327.00 291.82 0.89 (0.88-0.91; p<0.001) -284 -10.76%\nPlasmapheresis 513.31 469.24 0.91 (0.90-0.93; p<0.001) -227 -8.59%\nPlateletpheresis 722.32 740.23 1.02 (0.96-1.09; p=0.45) +558 +2.48%\nTotal 431.72 392.52 0.91 (0.90-0.92; p<0.001) -255 -9.08%\n*Variables used to calculate standardised rates: Donor age, gender, donation type, no. previous donations, and TB\nFigure 1: Plot graph for quarterly standardized rates for total adverse events per 10,000 donations\n39\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- Standardising demonstrated a significant relative risk reduction in each of\nthese events in 2022-23, translating to one less vasovagal, haematoma and painful arm event, for\nevery 637, 1,063 and 1,276 whole blood donations respectively.\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- Standardising also demonstrated a significant relative risk reduction in\nhaematoma, painful arm and mild citrate reactions in 2022- 23, translating to one less event for every\n313, 680 and 1,939 plasmapheresis donations respectively.\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n- The\n(standardised) relative risk of an infiltration event in 2022-23 was 1.42 (1.16-1.73; p<0.001) which\ntranslated to an additional event every 347 donations.\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n\n## Corporate Values and Operating Culture\n\n- [Page 12]\nHealth industry relevant organisation—main\nactivity type\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Health industry relevant organisation type\nMETEOR identifier: 372264\nDefinition: Describes a health industry relevant organisation based on\nits main activity, as represented by a code.*\nData Element Concept: Health industry relevant organisation—main activity type\nRepresentational attributes\nRepresentation class: Code\nData type: Number\nFormat: NNN\nMaximum character length: 3\nPermissible values: Value Meaning\nMain health care services organisation\n101 Hospital – public\n102 Hospital – private (excluding private free-\nstanding day hospital facility)\n103 Hospital – private free-standing day hospital\nfacility (excluding private non free-standing\nday hospital facility)\n104 Residential facility – mental health care\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- [Page 20]\nHealth-care incident—imputability score\nIdentifying and definitional attributes\nMetadata item type: Data element\nShort name: Imputability score\nMETEOR identifier: Not applicable\nDefinition: A hierarchical representation of the extent to which the\nadverse event is capable of being assigned or credited to the\ntransfusion. ∧\nData Element Concept: Health-care incident—imputability score\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: XX\nMaximum character length: 2\nPermissible values: Value Meaning\n01 Excluded\n02 Unlikely\n03 Possible\n04 Probable (likely)\n05 Definite (certain)\n99 Not assessable\nCollection and usage attributes\nGuide for use: Align the health service organisation assigned imputability with\nthe meanings provided below to generate the indicated code.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- [pages 20,21,22,23,24]\nm character length: 2\nPermissible values: Value Meaning\n01 Excluded\n02 Unlikely\n03 Possible\n04 Probable (likely)\n05 Definite (certain)\n99 Not assessable\nCollection and usage attributes\nGuide for use: Align the health service organisation assigned imputability with\nthe meanings provided below to generate the indicated code.\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)`\n- Table 2a: Total donor adverse event rates per 10,000 donations for FY 2016-17 to 2019-20\nTotal adverse event rate per 10,000 donations Comparison of FY 19-20 with 18-19\n(rate change from previous year) Relative Risk (95% Confidence Interval; p value)\nDonation Type 2016-17 2017-18 2018-19 2019-20 Number of donations for one additional event\nWhole Blood 310.57 299.05 297.09 321.76 1.08 (1.06-1.10; p<0.001)\n(-6.51) (-11.52) (-1.96) (+24.67) 406\nPlasmapheresis 188.89 261.60 324.13 455.08 1.40 (1.38-1.43; <0.001)\n(-10.20) (+72.71) (+62.53) (+130.95) 77\nPlateletpheresis 753.63 976.17 1,047.14 990.15 0.95 (0.90-0.99; p=0.03)\n(-49.02) (+222.54) (+70.97) (-56.99) -176\nTotal 268.17 295.12 325.50 404.30 1.24 (1.23-1.26; p<0.001)\n(-10.89) (+26.95) (+30.38) (+78.80) 127\n24\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 28]\nOFFICIAL\nTable 3a: Vasovagal rates in new and returned female and male whole blood donors for FY 2019-2020\nFemales Males\nNew or Returned Donor Events Donations Rate per Events Donation Rate per\n(n) (n) 10,000 (n) (n) 10,000\nReturned 2019-20 5,438 277,567 195.92 2,103 297,549 70.68\nReturned 2018-19 5,454 279,278 195.29 2,123 306,001 69.38\nNew 2019-20 5,452 73,098 745.85 2,792 53,261 524.21\nNew 2018-19 4,817 68,486 703.36 2,431 50,221 484.06\nRelative Risk (95% CI); p value Relative Risk (95% CI); p value\nComparison groups\n[number of donations for an extra event] [number of donations for an extra event]\nNew vs returned in 2019-20 3.81 (3.67-3.95; p<0.001) [19] 7.42 (7.01-7.84; p<0.001) [22]\nNew 2019 vs 2018 1.06 (1.02-1.10; p=0.002) [236] 1.08 (1.03-1.14; p=0.003) [249]\nReturning 2019 vs 2018 1.00 (0.97-1.04; p=0.87) 1.01 (0.96-1.08; p=0.55)\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- [Page 29]\nOFFICIAL\nFigure 1: Vasovagal rate per 10,000 donations (across all donation types) for males and females by age group for\n2019-20\nTable 3c: Vasovagal rates for new donors aged less than 30 and 30 years and over\nFemales Males\nVasovagal Donations Rate per 10,000 Vasovagal Donations Rate per 10,000\nevents (n) (n) donations events (n) (n) donations\nWhole blood <30 3,159 29,525 1069.94 1,536 18,874 813.82\nWhole blood ≥ 30 2,293 43,573 526.24 1,256 34,387 365.25\nPlasmapheresis <30 1,483 16,521 897.65 703 11,016 638.16\nPlasmapheresis ≥30 1,335 22,423 595.37 697 19,327 360.64\nComparison cohorts Relative Risk (95% CI); p value Relative Risk (95% CI); p value\n[number of donations for an extra event] [number of donations for an extra event]\nWhole blood <30 vs ≥30 2.03 (1.93-2.14; p<0.001) [19] 2.23 (2.07-2.40; p<0.001) [23]\nPlasma, <30 vs ≥30 1.51 (1.40-1.62; p<0.001) [33] 1.77 (1.60-1.\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Table 4b: Rates of vasovagal events with loss of consciousness per 10,000 donations 2016-17 to 2019-20\nDonation FY 2016-17 FY 2017-18 FY 2018-19 FY 2019-20 Comparison\nCategory 19/20 with 18/19\nn Rate per n Rate per n Rate per n Rate per Relative Risk P value\n10,000 10,000 10,000 10,000 (95% CI)\nWhole Blood 1,633 22.91 1,384 19.76 1,224 17.39 1,340 19.10 1.10 (1.02-1.19) p=0.02\nPlasmapheresis 415 7.17 543 8.40 718 9.63 752 9.14 0.95 (0.86-1.05) p=0.32\nPlateletpheresis 13 4.02 19 6.84 19 6.52 20 7.27 1.11 (0.60-2.09) p=0.73\nTotal 2,061 15.56 1,946 14.15 1,961 13.26 2,112 13.61 1.03 (0.97-1.09) p=0.41\n30\n Source: `other-pdfs/Haemovigilance-20Report-202019-20.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf)`\n- Table 1: Unadjusted total adverse event rates per 10,000 donations\nRate per 10,000 donations Comparison 2022-23 to 2021-22\nDonation type 19-20 20-21 21-22 22-23 RR2 (95% CI3; p value) Number of donations for % Change\none additional event*\nWhole blood 322.74 297.56 315.31 286.83 0.91 (0.89-0.93; p<0.001) -351 -9.03%\nPlasmapheresis 455.88 525.55 493.82 475.36 0.96 (0.95-0.98; p<0.001) -542 -3.74%\nPlateletpheresis 990.15 870.66 704.12 760.61 1.08 (1.01-1.15; p=0.02) +177 +8.02%\nTotal 405.17 429.57 413.92 392.50 0.95 (0.94-0.96; p<0.001) -467 -5.31%\n*a negative number indicates that the number of donations is for one less event\n2 Relative risk\n3 Confidence interval\nTable 2: Standardised* total adverse event rates per 10,000 donations\nRate per 10,000 donations Comparison 2022-23 to 2021-22\nDonation type 21-22 22-23 RR (95% CI; p value) Number of donations for % Change\none additional event\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py ` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf` - strategies - https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf\n- `pages/about.html` - pages - https://www.blood.gov.au/about-nba\n- `pages/homepage.html` - pages - https://www.blood.gov.au/haemovigilance-reporting\n- `pages/news-latest.html` - pages - https://www.blood.gov.au/latest-updates\n- `other-pdfs/Australian-20haemovigilance-20data-20at-20a-20glance-202019-20.pdf` - other-pdfs - https://www.blood.gov.au/sites/default/files/documents/2024-06/Australian%20haemovigilance%20data%20at%20a%20glance%202019-20.pdf\n- `other-pdfs/Haemovigilance-20Report-202019-20.pdf` - other-pdfs - https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf\n- `other-pdfs/Haemovigilance-20Report-202020-21.pdf` - other-pdfs - https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf\n- `other-pdfs/Haemovigilance-20Report-202021-22.pdf` - other-pdfs - https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf\n- `other-pdfs/Haemovigilance-20Report-202022-23.pdf` - other-pdfs - https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.\n- No annual report text source found.\n- No global comparison/case-study sources found.", "legislation_md": "# Haemovigilance Advisory Committee - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:11:49.012644+00:00\n**Entity ID**: B-003290\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 10\n- Unique legislation references found: 3\n\n| Type | Count |\n|---|---:|\n| Act | 3 |\n\n## Legislation References\n\n### Private Health Insurance Act 2007\n\n**Type**: Act\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Private+Health+Insurance+Act+2007\n\n**Sources**:\n- `other-pdfs/Haemovigilance-20Report-202022-23.pages.jsonl`\n\n**Evidence contexts**:\n- to engage with the private sector in haemovigilance reporting\nthrough a consultancy initiative as part of the NBA’s broad private sector engagement strategy.\nIn Australia there are 1,335 declared facilities to be a hospital, consistent with Section 121 of\nthe Private Health Insurance Act 2007. Of this there are 636 private and 699 public hospitals.\nSome of these hospitals receive blood and blood products, directly from our suppliers, through\npathology providers and through transfer arrangements. Further work on determining the\nnumber of hospitals\n Source: `other-pdfs/Haemovigilance-20Report-202022-23.pages.jsonl`\n\n### National Blood Authority Act 2003\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=National+Blood+Authority+Act+2003\n\n**Sources**:\n- `pages/about.html`\n\n**Evidence contexts**:\n- About NBA | National Blood Authority\n\nWho we are\nWe are a statutory agency established by the\nNational Blood Authority Act 2003\n(Cth)\n(Opens in a new tab/window)\n. We operate to achieve the policy objectives outlined in the\nNational Blood Agreement\n.\nWe manage and coordinate arrangements for the supply of blood, blood products and blood services in Australia. Under the national blood\n Source: `pages/about.html`\n\n### Therapeutic Goods Act 1989\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Therapeutic+Goods+Act+1989\n\n**Sources**:\n- `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pages.jsonl`\n\n**Evidence contexts**:\n- significance of anti-HLA antibodies).\nProduct defect A product defect is blood or a blood String 5 True or\ncomponent which does not meet the quality, False\nsafety and efficacy requirements set in the\nTherapeutic Goods Order No.1021 and 882\napproved under the Therapeutic Goods Act\n1989 or which contains (remaining)\ncontaminating agents despite screening,\ntesting and processing having been undertaken\nproperly (e.g. product discarded after positive\ninfection test result following a window\nperiod). Other examples may include bacterial\ncontamin\n Source: `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pages.jsonl`\n\n## Files Scanned\n\n- `pages/about.html` (page)\n- `pages/contact.html` (page)\n- `pages/homepage.html` (page)\n- `pages/news-latest.html` (page)\n- `other-pdfs/Australian-20haemovigilance-20data-20at-20a-20glance-202019-20.pages.jsonl` (pdf_pages)\n- `other-pdfs/Haemovigilance-20Report-202019-20.pages.jsonl` (pdf_pages)\n- `other-pdfs/Haemovigilance-20Report-202020-21.pages.jsonl` (pdf_pages)\n- `other-pdfs/Haemovigilance-20Report-202021-22.pages.jsonl` (pdf_pages)\n- `other-pdfs/Haemovigilance-20Report-202022-23.pages.jsonl` (pdf_pages)\n- `strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pages.jsonl` (pdf_pages)", "global_initiatives_md": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": "The purpose of this document is to detail the required data elements for the National Blood Authority’s (NBA) Australian Haemovigilance Minimum Data Set (AHMDS).", "purposes_source_page": 4, "how_we_deliver": null, "how_we_deliver_source_page": null, "government_priorities": [], "outcomes": [ { "name": "Outcome: Quality and Safety of Blood Transfusions", "description": "The AHMDS enables consistent data collection and analysis of transfusion related adverse events occurring in Australian health service organisations to improve the quality of national haemovigilance reporting.", "key_activities": [ "Data collection and analysis", "Reporting and monitoring" ], "source_page": 4 } ], "values": [], "values_framework_name": null, "kpi_targets_2025_26": [], "kpi_results_2024_25": [], "_source_urls": { "annual_report_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "corporate_plan_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf" } }, "ideas": [ { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "[Page 18]\nPatient—outcome severity\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Outcome severity\nMETEOR identifier: Not applicable\nDefinition: Hierarchical categories to define harm done to the patient\nas a result of an adverse event. ∧\nData Element Concept: Patient—outcome severity\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: [X(21)]\nMaximum character length: 21\nPermissible values:\nValue Meaning\nNo morbidity No ill effects, no clinical effects\nMinor The recipient may have required medical\nmorbidity intervention (such as symptomatic\ntreatment) but lack of such would not\nhave resulted in permanent damage or\nimpairment of a body function\nSevere The recipient required in-patient\nmorbidity hospitalisation or prolongation of\nhospitalisation directly attributable to the\nevent; and/or\n- the adverse event resulted in", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "[Page 18]\nPatient—outcome severity\nIdentifying and definitional attributes\nMetadata item type: Data Element\nShort name: Outcome severity\nMETEOR identifier: Not applicable\nDefinition: Hierarchical categories to define harm done to the patient\nas a result of an adverse event. ∧\nData Element Concept: Patient—outcome severity\nRepresentational attributes\nRepresentation class: Code\nData type: String\nFormat: [X(21)]\nMaximum character length: 21\nPermissible values:\nValue Meaning\nNo morbidity No ill effects, no clinical effects\nMinor The recipient may have required medical\nmorbidity intervention (such as symptomatic\ntreatment) but lack of such would not\nhave resulted in permanent damage or\nimpairment of a body function\nSevere The recipient required in-patient\nmorbidity hospitalisation or prolongation of\nhospitalisation directly attributable to the\nevent; and/or\n- the adverse event resulted in", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "[Page 15]\nTable 9 highlights that 68% of adverse events were reported to be related to red cell transfusions,\ncompared to red cells units issued being 62% of total fresh blood products issued in 2020-21,\nfollowed by platelets (14%) and fresh frozen plasma (8%).", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/Haemovigilance-20Report-202020-21.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "[Page 15]\nTable 9 highlights that 68% of adverse events were reported to be related to red cell transfusions,\ncompared to red cells units issued being 62% of total fresh blood products issued in 2020-21,\nfollowed by platelets (14%) and fresh frozen plasma (8%).", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/Haemovigilance-20Report-202020-21.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "[pages 25,26,27]\nance in\nresponse to targeted messaging for pre-donation fluid intake and in-centre applied muscle tensing\nexercises, staff phlebotomy excellence training, the change to a smaller gauge needle and\nexperience with the plasma machines introduced from May 2019.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "[pages 25,26,27]\nance in\nresponse to targeted messaging for pre-donation fluid intake and in-centre applied muscle tensing\nexercises, staff phlebotomy excellence training, the change to a smaller gauge needle and\nexperience with the plasma machines introduced from May 2019.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/Haemovigilance-20Report-202021-22.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Case Processing", "scale": "small", "title": "Triage queue for stuck or ageing cases", "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.", "quote": "Product defect A product defect is blood or a blood String 5 True or\ncomponent which does not meet the quality, False\nsafety and efficacy requirements set in the\nTherapeutic Goods Order No.1021 and 882\napproved under the Therapeutic Goods Act\n1989 or which contains (remaining)\ncontaminating agents despite screening,\ntesting and processing having been undertaken\nproperly (e.g. product discarded after positive\ninfection test result following a window\nperiod).", "impact": "Medium", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Case Processing", "scale": "large", "title": "End-to-end case processing redesign", "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.", "quote": "Product defect A product defect is blood or a blood String 5 True or\ncomponent which does not meet the quality, False\nsafety and efficacy requirements set in the\nTherapeutic Goods Order No.1021 and 882\napproved under the Therapeutic Goods Act\n1989 or which contains (remaining)\ncontaminating agents despite screening,\ntesting and processing having been undertaken\nproperly (e.g. product discarded after positive\ninfection test result following a window\nperiod).", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Participation", "scale": "small", "title": "Consultation feedback summaries with response tracking", "idea": "Summarise consultation submissions by theme and publish what changed in response.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "Medium", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "category": "Citizen Participation", "scale": "large", "title": "Always-on policy participation platform", "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.", "quote": "[Page 13]\n118 Retail sale/supplier of medical goods – hearing\naids\n119 Retail sale/supplier of medical goods –\ndispensing community pharmacist\n120 Retail sale/supplier of medical goods – other\n121 Public health program service provider\n122 General health administration service\nprovider\n123 Private health insurance\n188 Other Main Health Care Service providers\n198 Regional health service not further defined\n199 State/territory health authority not further\ndefined\n200 Secondary/non-Health Care Services\norganisation\n201 Pharmaceutical industry\n202 University\n203 Non-health related insurance\n204 Residential aged care facility\n288 Other Secondary/non-Health Care Services\norganisation\nCollection and usage attributes\nGuide for use: It is anticipated that only codes 101, 102, or 103 will be\nreported to the National Haemovigilance Program.", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] } ], "legislation_administered": [], "artifacts": [ { "category": "strategies", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf", "file": "strategies/AHMDS-20--20Oct-202024-20--20FINAL-20pdf.pdf", "bytes": 1753476, "link_text": "Australian Haemovigilance Minimum Data Set" }, { "category": "other-pdfs", "year": "2022-23", "url": "https://www.blood.gov.au/sites/default/files/documents/2026-02/Haemovigilance%20Report%202022-23.pdf", "file": "other-pdfs/Haemovigilance-20Report-202022-23.pdf", "bytes": 2391986, "link_text": "Haemovigilance Report 2022-23 (pdf)" }, { "category": "other-pdfs", "year": "2021-22", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202021-22.pdf", "file": "other-pdfs/Haemovigilance-20Report-202021-22.pdf", "bytes": 1421478, "link_text": "Haemovigilance Report 2021-22 (pdf)" }, { "category": "other-pdfs", "year": "2020-21", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-03/Haemovigilance%20Report%202020-21.pdf", "file": "other-pdfs/Haemovigilance-20Report-202020-21.pdf", "bytes": 1585373, "link_text": "Haemovigilance Report 2020-21 (pdf)" }, { "category": "other-pdfs", "year": "2019-20", "url": "https://www.blood.gov.au/sites/default/files/documents/2024-06/Australian%20haemovigilance%20data%20at%20a%20glance%202019-20.pdf", "file": "other-pdfs/Australian-20haemovigilance-20data-20at-20a-20glance-202019-20.pdf", "bytes": 349393, "link_text": "Australian Haemovigilance at a Glance 2019-20 (pdf)" }, { "category": "other-pdfs", "year": "2019-20", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-07/Haemovigilance%20Report%202019-20.pdf", "file": "other-pdfs/Haemovigilance-20Report-202019-20.pdf", "bytes": 1399136, "link_text": "Australian Haemovigilance Report 2019-20 (pdf)" }, { "category": "annual-reports", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "file": "annual-reports/2025.pdf", "bytes": 3522745, "link_text": "Annual Report" }, { "category": "corporate-plans", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "file": "corporate-plans/2025.pdf", "bytes": 6435684, "link_text": "Corporate Plan" } ], "_meta": { "snapshot_built_at": "2026-05-13T11:02:51+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "Haemovigilance-Advisory-Committee", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "strategies\\AHMDS-20--20Oct-202024-20--20FINAL-20pdf.txt", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-09/AHMDS%20-%20Oct%202024%20-%20FINAL%20pdf.pdf", "year": "AHMDS-20--20Oct-202024-20--20FINAL-20pdf" }, "usage": { "input_tokens": 11917, "output_tokens": 276, "total_tokens": 12193, "model": "nova-micro" }, "cost_usd": 0.000455735, "elapsed_seconds": 2.24, "generated_at": "2026-05-13T10:33:31+00:00" }, "ideas_manifest": { "entity_id": "B-003290", "entity_name": "Haemovigilance Advisory Committee", "folder_name": "Haemovigilance-Advisory-Committee", "generated_at": "2026-05-09T23:05:41.455399+00:00", "idea_count": 12, "markdown": "ideas/Haemovigilance-Advisory-Committee_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "Haemovigilance-Advisory-Committee_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }